Physician profile
Rezwan Ashdji
NPI 1730190042
$805.38
in general payments reported to CMS, 2019-2025
15 companies · $60.23 in 2025
The $60.23 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $275 · 2021: $120 · 2022: $35.11 · 2023: $38.56 · 2024: $129 · 2025: $60.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $227.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $265.37 | 2020-2021 | |
| Novo Nordisk INC | $191.10 | 2019-2024 | Wegovy |
| Astellas Pharma US INC | $61.06 | 2024-2025 | Veozah |
| Glaxosmithkline, LLC. | $41.07 | 2020-2021 | |
| Esperion Therapeutics, INC. | $40.26 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $32.51 | 2020 | |
| Janssen Pharmaceuticals, INC | $27.60 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $24.53 | 2019 | |
| Optinose US, INC. | $22.89 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $22.70 | 2023 | Breztri |
| Melinta Therapeutics, LLC | $17.43 | 2019 | |
| Abbott Laboratories | $15.86 | 2023 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.26 | 2019 | |
| Amgen INC. | $15.23 | 2025 | Repatha, Otezla |
| Hikma Pharmaceuticals USA | $12.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rezwan Ashdji listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.